Nilufar Khushvakova, Gulrukh Davronova
The use of citoflavin is effective in the treatment of patients with CHF for preventive therapy in order to maintain the stability of auditory thresholds in the absence of a mutation of the А1555 G mitochondrial gene, the presence of which is a factor in the progression of hearing loss, which requires electroacoustic correction with a plan for future cochlear implantation. In the group
with standard treatment, no statistically significant changes were found, however, it should be noted that monotherapy is preferable both from an economic point of view and a medical position, when the use of several drugs is an expensive and time-consuming process that does not always entail a positive result. As a result of the research, it was shown that complex treatment with the preparation of cytoflavin leads to an improvement in cerebral circulation and coronary blood flow, activates metabolic processes in the central nervous system, contributes to a more pronounced regression of neurological symptoms in the main group 2 to 3 times compared to the control group.
